兆瓦级超充桩
Search documents
800V新能源车渗透率破10%,超充电池、超充桩等率先升级
高工锂电· 2026-02-26 11:00
摘要 超充生态协同升级。 800V 高压平台正逐渐从过去的高端配置成为主流标配。 从一组数据来看,相关机构测算 800V 高压平台车型在 2025 年的渗透率已超过 10% ,销量接近 150 万辆,预测在 2026 年实现 15% 的渗 透。 800V 高压平台电车渗透率上扬的同时,电池、超充桩等相关配套也迎来了同步升级。 电池方面 , 800V 高压平台下选用的主流电池为 5C 电池。小鹏 G9 Max 、蔚来 ET9 、理想 MEGA 、极氪 007/009 、小米 SU7 ultral/YU7 等都搭载了 5C 电池,供应商主要为宁德时代、中创新航、亿纬锂能等头部企业。 进入 2025 年,越来越多的更多主机厂发布 800V 及以上车型。其中, 理想 i6 的爆单,将 5C 超充电池成功切入 20-30 万价格区间纯电 SUV 最大用户画像,也荡起了 5C 超充电池使用磷酸铁锂材料的涟漪。 过去,超充电池为实现更高的倍率,一般采用三元材料体系 。此前,宁德时代三元 6C 电池此前已实现上车、中创新航、亿纬锂能则带来了高镍 6C 大圆柱电池、蜂巢能源则带来了 6C 短刀电池。 如今,随着 3.5-4 代 ...
比亚迪方程豹要掀了整个市场 竟然一口气发布5款新车
Xin Lang Cai Jing· 2026-01-29 00:59
Core Insights - The company, Fangchengbao, has rapidly gained market traction with its Ti7 model, selling over 50,000 units in just 80 days, prompting competitors like BYD to adjust production lines to meet demand [1] - However, the average selling price of its vehicles has decreased significantly, from 330,000 to 240,000, indicating a shift towards lower-end models [1] - In 2026, Fangchengbao plans to launch five new models, expanding its price range and targeting various consumer segments [2][3][4] Model Launches - The first model, Ti3 DM-i, is priced in the mid-teens and aims for a fuel consumption of 2.6 liters with a range of 2,000 kilometers, targeting consumers considering models like Haval H6 and Changan CS75 [2] - The second model, Ti5, is a mid-size SUV priced between 180,000 and 220,000, designed to compete with Tesla Model Y and AITO M5, focusing on practicality and unique design [2] - The third model, Mg7, is Fangchengbao's first sedan with a price range of 230,000 to 280,000, boasting over 1,000 kilometers of electric range and advanced features [3] - The fourth model, Ti9, is a flagship vehicle priced above 300,000, equipped with high-end technologies and targeting high-end family users [3] - The fifth model is an updated version of the Leopard 5, aimed at maintaining the brand's core market while enhancing comfort and technology [4] Technological Advancements - Fangchengbao's vehicles will utilize BYD's fifth-generation DM hybrid system, achieving over 46% thermal efficiency and reducing fuel consumption to below 3 liters [4] - The company is also implementing advanced driving technologies across its lineup, including the "Tianshen Eye" hardware for intelligent driving capabilities [5] - Interior features include a standardized 15.6-inch rotating central control screen and eco-friendly materials, with a focus on user experience [6] Market Positioning - Fangchengbao's brand positioning has evolved from being a "BYD off-road brand" to a "full-scenario technology brand," with a product line covering various vehicle types and price ranges from 130,000 to 350,000 [6] - The company has observed a 15% decrease in foot traffic for Tesla Model Y following the announcement of new models, indicating a shift in consumer interest [6] - Fangchengbao aims to deliver 500,000 vehicles in 2026, significantly increasing production capacity and supply chain efficiency [8] Competitive Strategy - Fangchengbao is strategically targeting competitors' weaknesses, such as offering hybrid technology at lower prices and enhancing interior comfort compared to rivals [7] - The company has received over 20,000 pre-orders for the Ti3 DM-i within a week of its announcement, with a significant portion coming from consumers initially considering traditional fuel SUVs [7] - The rapid product development cycle, taking only 18 months from design to production, showcases Fangchengbao's vertical integration capabilities within BYD [8]
*ST惠程(002168) - 002168*ST惠程投资者关系管理信息20250519
2025-05-19 11:40
Group 1: Company Overview and Business Segments - The company operates in four main business segments: power distribution equipment, electric vehicle charging stations, photovoltaic and wind power EPC, and biomedicine [2][3][11] - The acquisition of 51% of Rui'en Pharmaceutical is a strategic move to enhance the company's presence in the biomedicine sector [11][12] Group 2: Financial Performance and Goals - In Q1 2025, the company reported a revenue of 60.76 million CNY, a year-on-year increase of 94.47% due to the consolidation of Rui'en Pharmaceutical [11][12] - The company aims to improve its overall financial performance and mitigate delisting risks by enhancing operational management and cost control [3][4][12] Group 3: Risk Management and Compliance - The company is under delisting risk warning due to negative net profit and low revenue, with efforts being made to resolve these issues [4][6][12] - The company plans to apply for the removal of risk warnings once it meets the necessary criteria set by the Shenzhen Stock Exchange [4][6] Group 4: Strategic Initiatives and Future Plans - The company intends to expand its market presence both domestically and internationally, focusing on partnerships and order fulfillment [4][11] - Emphasis will be placed on technological advancements and maintaining customer relationships to enhance operational efficiency and brand reputation [4][11] Group 5: Shareholder Engagement and Market Confidence - The company reassures shareholders that there are no current plans for major asset disposals or reductions in shareholding by major stakeholders [13] - Continuous efforts are being made to improve shareholder value and market confidence through strategic management and operational improvements [13]